School of Veterinary Nursing & Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonancho, Musashino, Tokyo 180-8602, Japan.
J Vet Med Sci. 2020 Jun 16;82(6):695-698. doi: 10.1292/jvms.19-0309. Epub 2020 Apr 20.
Insulin degludec (IDeg) is a long-acting basal insulin recently developed for use in humans. This study aimed to investigate the effects of IDeg on glycemic control in diabetic cats. Changes in body weight, IDeg dosage, and glycated albumin (GA) were evaluated at 0, 1, 3, 6, 9, and 12 months following initiation of IDeg. A significant decrease in GA was observed and a mean GA level below 25% was achieved between 3 and 12 months. Furthermore, a significant increase in body weight was observed between 3 and 12 months. The mean IDeg dose was 0.75 ± 0.68 IU/kg/day at 12 months. Taken together, long-term glycemic control was successfully achieved in diabetic cats using IDeg.
胰岛素德谷（IDeg）是一种最近开发用于人类的长效基础胰岛素。本研究旨在探讨 IDeg 对糖尿病猫血糖控制的影响。在开始使用 IDeg 后 0、1、3、6、9 和 12 个月时，评估体重、IDeg 剂量和糖化白蛋白（GA）的变化。结果发现 GA 显著下降，并且在 3 至 12 个月期间达到了低于 25%的平均 GA 水平。此外，体重在 3 至 12 个月之间显著增加。在 12 个月时，平均 IDeg 剂量为 0.75 ± 0.68 IU/kg/天。总之，使用 IDeg 成功地实现了糖尿病猫的长期血糖控制。
